Walvax Biotechnology Balance Sheet Health
Financial Health criteria checks 5/6
Walvax Biotechnology has a total shareholder equity of CN¥11.4B and total debt of CN¥791.0M, which brings its debt-to-equity ratio to 6.9%. Its total assets and total liabilities are CN¥15.4B and CN¥4.0B respectively. Walvax Biotechnology's EBIT is CN¥648.7M making its interest coverage ratio -8.8. It has cash and short-term investments of CN¥4.1B.
Key information
6.9%
Debt to equity ratio
CN¥791.02m
Debt
| Interest coverage ratio | -8.8x |
| Cash | CN¥4.11b |
| Equity | CN¥11.43b |
| Total liabilities | CN¥3.95b |
| Total assets | CN¥15.39b |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: 300142's short term assets (CN¥8.5B) exceed its short term liabilities (CN¥3.0B).
Long Term Liabilities: 300142's short term assets (CN¥8.5B) exceed its long term liabilities (CN¥975.5M).
Debt to Equity History and Analysis
Debt Level: 300142 has more cash than its total debt.
Reducing Debt: 300142's debt to equity ratio has increased from 0.6% to 6.9% over the past 5 years.
Debt Coverage: 300142's debt is well covered by operating cash flow (108.1%).
Interest Coverage: 300142 earns more interest than it pays, so coverage of interest payments is not a concern.